Cargando…

Type 2 Innate Lymphoid Cells: Protectors in Type 2 Diabetes

Type 2 innate lymphoid cells (ILC2) are the innate counterparts of Th2 cells and are critically involved in the maintenance of homeostasis in a variety of tissues. Instead of expressing specific antigen receptors, ILC2s respond to external stimuli such as alarmins released from damage. These cells h...

Descripción completa

Detalles Bibliográficos
Autores principales: Painter, Jacob D., Akbari, Omid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8416625/
https://www.ncbi.nlm.nih.gov/pubmed/34489979
http://dx.doi.org/10.3389/fimmu.2021.727008
_version_ 1783748228208918528
author Painter, Jacob D.
Akbari, Omid
author_facet Painter, Jacob D.
Akbari, Omid
author_sort Painter, Jacob D.
collection PubMed
description Type 2 innate lymphoid cells (ILC2) are the innate counterparts of Th2 cells and are critically involved in the maintenance of homeostasis in a variety of tissues. Instead of expressing specific antigen receptors, ILC2s respond to external stimuli such as alarmins released from damage. These cells help control the delicate balance of inflammation in adipose tissue, which is a determinant of metabolic outcome. ILC2s play a key role in the pathogenesis of type 2 diabetes mellitus (T2DM) through their protective effects on tissue homeostasis. A variety of crosstalk takes place between resident adipose cells and ILC2s, with each interaction playing a key role in controlling this balance. ILC2 effector function is associated with increased browning of adipose tissue and an anti-inflammatory immune profile. Trafficking and maintenance of ILC2 populations are critical for tissue homeostasis. The metabolic environment and energy source significantly affect the number and function of ILC2s in addition to affecting their interactions with resident cell types. How ILC2s react to changes in the metabolic environment is a clear determinant of the severity of disease. Treating sources of metabolic instability via critical immune cells provides a clear avenue for modulation of systemic homeostasis and new treatments of T2DM.
format Online
Article
Text
id pubmed-8416625
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84166252021-09-05 Type 2 Innate Lymphoid Cells: Protectors in Type 2 Diabetes Painter, Jacob D. Akbari, Omid Front Immunol Immunology Type 2 innate lymphoid cells (ILC2) are the innate counterparts of Th2 cells and are critically involved in the maintenance of homeostasis in a variety of tissues. Instead of expressing specific antigen receptors, ILC2s respond to external stimuli such as alarmins released from damage. These cells help control the delicate balance of inflammation in adipose tissue, which is a determinant of metabolic outcome. ILC2s play a key role in the pathogenesis of type 2 diabetes mellitus (T2DM) through their protective effects on tissue homeostasis. A variety of crosstalk takes place between resident adipose cells and ILC2s, with each interaction playing a key role in controlling this balance. ILC2 effector function is associated with increased browning of adipose tissue and an anti-inflammatory immune profile. Trafficking and maintenance of ILC2 populations are critical for tissue homeostasis. The metabolic environment and energy source significantly affect the number and function of ILC2s in addition to affecting their interactions with resident cell types. How ILC2s react to changes in the metabolic environment is a clear determinant of the severity of disease. Treating sources of metabolic instability via critical immune cells provides a clear avenue for modulation of systemic homeostasis and new treatments of T2DM. Frontiers Media S.A. 2021-08-19 /pmc/articles/PMC8416625/ /pubmed/34489979 http://dx.doi.org/10.3389/fimmu.2021.727008 Text en Copyright © 2021 Painter and Akbari https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Painter, Jacob D.
Akbari, Omid
Type 2 Innate Lymphoid Cells: Protectors in Type 2 Diabetes
title Type 2 Innate Lymphoid Cells: Protectors in Type 2 Diabetes
title_full Type 2 Innate Lymphoid Cells: Protectors in Type 2 Diabetes
title_fullStr Type 2 Innate Lymphoid Cells: Protectors in Type 2 Diabetes
title_full_unstemmed Type 2 Innate Lymphoid Cells: Protectors in Type 2 Diabetes
title_short Type 2 Innate Lymphoid Cells: Protectors in Type 2 Diabetes
title_sort type 2 innate lymphoid cells: protectors in type 2 diabetes
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8416625/
https://www.ncbi.nlm.nih.gov/pubmed/34489979
http://dx.doi.org/10.3389/fimmu.2021.727008
work_keys_str_mv AT painterjacobd type2innatelymphoidcellsprotectorsintype2diabetes
AT akbariomid type2innatelymphoidcellsprotectorsintype2diabetes